Results 181 to 190 of about 388,394 (322)

Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia

open access: yesAmerican Journal of Hematology, Volume 98, Issue 2, Page 338-347, February 2023., 2023
Abstract Bruton tyrosine kinase (BTK) inhibitors have taken a central role in the management of patients with Waldenström macroglobulinemia and are the only agents approved by the Food and Drug Administration (FDA) to treat these patients. Although associated with high rates of durable responses, unmet needs with BTK inhibitor therapy include ...
Jorge J. Castillo   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy